Emergent Biosolutions Inc (NYSE:EBS) CEO Daniel Abdun-Nabi sold 90,776 shares of the business’s stock in a transaction dated Wednesday, September 5th. The shares were sold at an average price of $60.18, for a total transaction of $5,462,899.68. Following the completion of the sale, the chief executive officer now owns 257,343 shares in the company, valued at $15,486,901.74. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Shares of NYSE:EBS opened at $57.71 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.15 and a current ratio of 5.59. The stock has a market cap of $2.95 billion, a price-to-earnings ratio of 30.37, a price-to-earnings-growth ratio of 1.24 and a beta of 1.25. Emergent Biosolutions Inc has a 1 year low of $36.38 and a 1 year high of $64.00.

Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported $1.07 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.88 by $0.19. The company had revenue of $220.20 million for the quarter, compared to analyst estimates of $208.94 million. Emergent Biosolutions had a net margin of 16.55% and a return on equity of 15.09%. The business’s revenue for the quarter was up 118.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.13 earnings per share. analysts anticipate that Emergent Biosolutions Inc will post 2.37 EPS for the current fiscal year.

Several analysts recently issued reports on the stock. Chardan Capital boosted their price objective on shares of Emergent Biosolutions from $60.00 to $66.00 and gave the company a “buy” rating in a report on Tuesday, September 4th. Cowen restated a “hold” rating and issued a $49.00 price objective on shares of Emergent Biosolutions in a report on Wednesday, August 29th. Wells Fargo & Co set a $65.00 price objective on shares of Emergent Biosolutions and gave the company a “hold” rating in a report on Wednesday, August 29th. Cantor Fitzgerald set a $62.00 price objective on shares of Emergent Biosolutions and gave the company a “buy” rating in a report on Tuesday, August 28th. Finally, Zacks Investment Research lowered shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a report on Monday, August 20th. Four equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $59.88.

A number of large investors have recently modified their holdings of EBS. Stratos Wealth Partners LTD. purchased a new stake in Emergent Biosolutions during the first quarter worth about $134,000. PNC Financial Services Group Inc. increased its stake in Emergent Biosolutions by 108.6% during the first quarter. PNC Financial Services Group Inc. now owns 2,847 shares of the biopharmaceutical company’s stock worth $149,000 after purchasing an additional 1,482 shares during the period. SG Americas Securities LLC purchased a new stake in Emergent Biosolutions during the first quarter worth about $171,000. Financial Gravity Wealth Inc. purchased a new stake in Emergent Biosolutions during the first quarter worth about $190,000. Finally, Sei Investments Co. increased its stake in Emergent Biosolutions by 5,992.1% during the first quarter. Sei Investments Co. now owns 3,838 shares of the biopharmaceutical company’s stock worth $202,000 after purchasing an additional 3,775 shares during the period. Institutional investors own 83.01% of the company’s stock.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.

Read More: Marijuana Stocks Investing Considerations

Insider Buying and Selling by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.